Nevertheless, Tufts is keeping their money. There is nothing wrong with rejecting dirty money, but Tufts has done no such thing. As I have posted previously, Arthur Sackler sold his interest in Purdue Pharma long before OxyContin was developed or marketed. What is especially galling is that Tufts seems aware that Arthur Sackler did nothing wrong. According to the Dean: “The Sackler name is a problem, whether it’s the Arthur Sackler name, or all the Sackler names .

Source: Forbes December 07, 2019 12:56 UTC